Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 60-year-old female is evaluated in the primary care clinic for the management of elevated blood pressure. Over the past three clinic visits, her blood pressure has consistently averaged 154/96154/96 mmHg. Her past medical history is significant for bipolar I disorder, which has been well controlled on lithium carbonate for the past eight years without mood instability. She also has moderate persistent asthma, managed with a daily inhaled corticosteroid and as-needed albuterol. Her current vital signs are: heart rate 7878/min, respiratory rate 1414/min, and blood pressure 152/94152/94 mmHg. Physical examination is unremarkable, with clear lungs bilaterally and a regular heart rhythm. Recent laboratory studies reveal a serum creatinine of 0.90.9 mg/dL, serum potassium of 4.14.1 mEq/L, and a serum lithium level of 0.80.8 mEq/L (therapeutic range: 0.6−1.20.6-1.2 mEq/L). The physician decides to initiate pharmacologic monotherapy for essential hypertension. Which of the following is the most appropriate pharmacologic intervention for this patient?

  1. A
    Lisinopril
  2. B
    Chlorthalidone
  3. AmlodipineCevap
  4. D
    Propranolol
  5. E
    Valsartan

Cevap

Amlodipine is the most appropriate first-line antihypertensive for this patient, as it safely lowers blood pressure without interacting with her chronic lithium therapy or exacerbating her asthma.
Amlodipine is a dihydropyridine calcium channel blocker and a first-line agent for the treatment of essential hypertension. In a patient with concurrent bipolar disorder on lithium and asthma, it is the safest choice because it does not significantly alter the renal clearance of lithium, nor does it affect bronchial smooth muscle tone. It effectively lowers blood pressure without exacerbating her underlying airway disease or precipitating neurologic toxicity from lithium accumulation.

Adım Adım Çözüm

1
Identify the primary clinical objective
The patient requires initiation of a first-line antihypertensive medication for newly diagnosed essential hypertension.
Blood pressure measurements have consistently remained elevated across multiple visits, indicating a need for pharmacotherapy.
2
Analyze the patient's comorbidities for therapeutic constraints
The patient has bipolar I disorder currently managed with lithium, and moderate persistent asthma.
Comorbidities heavily dictate the safety profile required for new prescriptions, especially to avoid drug-drug interactions or disease exacerbations.
3
Evaluate first-line antihypertensive classes against the patient's lithium use
Thiazide diuretics, ACE inhibitors, and ARBs must be excluded.
These three classes decrease renal clearance of lithium by promoting its reabsorption in the proximal tubule, leading to a high risk of lithium toxicity (e.g., ataxia, tremors, encephalopathy).
4
Evaluate remaining antihypertensive options against the patient's asthma
Non-selective beta-blockers must be excluded.
Medications that block beta-2 receptors can trigger severe bronchospasm in patients with reactive airway disease.
5
Select the optimal agent
Amlodipine (a calcium channel blocker) is chosen.
It is a first-line antihypertensive that effectively lowers blood pressure, does not significantly alter lithium clearance, and is safe in asthma.

Anahtar Kavram

Patients taking lithium require careful selection of concurrent medications; thiazide diuretics, ACE inhibitors, NSAIDs, and ARBs significantly reduce renal lithium clearance and can rapidly precipitate toxicity. Calcium channel blockers are generally safe alternatives for managing hypertension in these patients.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru